Riccardo Asero1, Giorgio W Canonica, Antonio Cristaudo, Maria T Fierro, Giampiero Girolomoni, Angelo V Marzano, Eustachio Nettis, Patrizia Pepe, Paolo Pigatto, Oliviero Rossi. 1. aAmbulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano bPersonalized Medicine Asthma and Allergy Clinic, Humanitas Research Hospital, Humanitas University, Rozzano, Milan cDepartment of Dermato-Allergology, San Gallicano Dermatological Institute, IRCCS, Rome dDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, Turin eSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona fUnità Operativa di Dermatologia, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan gDepartment of Allergy and Clinical Immunology, University of Bari, Bari hDermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena iUnit of Dermatology, Department of Biomedical, Surgical, and Dental Sciences, IRCCS Galeazzi Hospital, University of Milan, Milan jSOD Immunoallergologia Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.
Abstract
PURPOSE OF REVIEW: The humanized anti-IgE antibody omalizumab has been available for patients with chronic spontaneous urticaria (CSU) in Italy since 2015. This review summarizes the unresolved issues and unmet therapeutic needs associated with omalizumab and discusses practical recommendations for its use in the management of CSU. RECENT FINDINGS: Although modern second-generation H1-antihistamines are the standard of care for patients with CSU, adjunctive treatments (including omalizumab) may be required for effective control of symptoms in many patients. Evidence from clinical trials and experience from daily clinical practice suggest that the use of omalizumab in patients with CSU who have inadequate response to H1-antihistamines remains challenging. SUMMARY: Based on current international guidelines, omalizumab labelling information and our experience in clinical practice, we provide treatment recommendations regarding the use of omalizumab in patients with CSU. These include: optimal treatment duration, the use of concomitant antihistamine therapy, the definition and management of disease relapse after treatment, and the management of patients with late or no response to treatment.
PURPOSE OF REVIEW: The humanized anti-IgE antibody omalizumab has been available for patients with chronic spontaneous urticaria (CSU) in Italy since 2015. This review summarizes the unresolved issues and unmet therapeutic needs associated with omalizumab and discusses practical recommendations for its use in the management of CSU. RECENT FINDINGS: Although modern second-generation H1-antihistamines are the standard of care for patients with CSU, adjunctive treatments (including omalizumab) may be required for effective control of symptoms in many patients. Evidence from clinical trials and experience from daily clinical practice suggest that the use of omalizumab in patients with CSU who have inadequate response to H1-antihistamines remains challenging. SUMMARY: Based on current international guidelines, omalizumab labelling information and our experience in clinical practice, we provide treatment recommendations regarding the use of omalizumab in patients with CSU. These include: optimal treatment duration, the use of concomitant antihistamine therapy, the definition and management of disease relapse after treatment, and the management of patients with late or no response to treatment.
Authors: Désirée E S Larenas-Linnemann; Claudio A S Parisi; Carla Ritchie; Ricardo Cardona-Villa; Ivan Cherrez-Ojeda; Annia Cherrez; Luis Felipe Ensina; Elizabeth Garcia; Iris V Medina; Mónica Rodríguez-González; Jorge Mario Sánchez Caraballo Journal: Curr Allergy Asthma Rep Date: 2018-05-09 Impact factor: 4.806
Authors: Ivan Cherrez-Ojeda; Marcus Maurer; Jonathan A Bernstein; Emanuel Vanegas; Miguel Felix; German D Ramon; Luis Felipe Ensina; José Ignacio Larco Sousa; Edgar Emilio Matos Benavides; R Cardona Villa; P Latour Staffeld; Blanca María Morfin-Maciel; Jose Mori; Paul Wilches C; Valeria L Mata; Annia Cherrez Journal: World Allergy Organ J Date: 2019-02-23 Impact factor: 4.084